Huang et al. (32) used the CRISPR/Cas9 system to target exon 17 of the EGFR gene in glioma cells, thereby activating the inhibitory modification of UBXN1 and inhibiting tumor necrosis factor in these cells. This evidence concerns the gene TNF and central nervous system cancer.